8-K: Brainstorm Secures Debt, Advances ALS Trial Amidst Low Cash

Brainstorm Cell Therapeutics announced Q3 2025 financial results and secured a $143,750 promissory note to fund operations and advance its NurOwn Phase 3b ALS trial.

Summary

• Brainstorm Cell Therapeutics Inc. entered into a securities purchase agreement with Labrys Fund II, L.P. for a promissory note with a principal amount of $143,750, including an $18,750 original issue discount.
• The company received $121,500 in funds after deducting $3,500 for legal fees related to the financing.
• The promissory note is convertible into common stock upon an event of default at a 25% discount to the lowest trading price over the preceding 20 trading days, subject to a 4.99% beneficial ownership limitation.
• Amortization payments of $22,589.28 are due monthly from May 11, 2026, to October 9, 2026, with the note maturing on November 10, 2026.
• The U.S. FDA has cleared the planned Phase 3b ENDURANCE clinical trial for NurOwn (MSC-NTF) for ALS, which is expected to enroll approximately 200 participants.
• The Phase 3b trial includes a 24-week randomized, double-blind, placebo-controlled period (Part A) and a subsequent 24-week open-label extension (Part B), with Part A data intended to support a Biologics License Application (BLA).
• Cash, cash equivalents, and restricted cash were approximately $0.23 million as of September 30, 2025.
• Research and development expenditures, net, for Q3 2025 were $0.9 million, a decrease from $1.0 million in Q3 2024.
• General and administrative expenses for Q3 2025 were $1.1 million, down from $2.0 million in Q3 2024.
• Net loss for Q3 2025 was $2.1 million, an improvement from a net loss of $2.7 million in Q3 2024.
• Net loss per share for Q3 2025 was $0.19, compared to $0.51 in Q3 2024.
• A Citizen Petition was filed with the FDA by representatives of the ALS community, requesting a renewed regulatory review of NurOwn data, which the company acknowledges as a constructive development.

Sentiment

Score: 4

Explanation: The sentiment is mixed, leaning negative due to the precarious financial position (very low cash, ongoing losses, dilutive financing) despite positive clinical progress (FDA clearance for Phase 3b trial). The immediate need for capital and the dilutive terms of the current financing weigh heavily on the overall outlook.

Positives

• FDA clearance for the Phase 3b ENDURANCE clinical trial of NurOwn for ALS marks significant regulatory progress.
• Reduced net loss for Q3 2025 to $2.1 million from $2.7 million in Q3 2024, indicating improved operational efficiency.
• Decreased research and development expenses to $0.9 million in Q3 2025 from $1.0 million in Q3 2024.
• General and administrative expenses significantly decreased to $1.1 million in Q3 2025 from $2.0 million in Q3 2024.
• The ALS community's Citizen Petition to the FDA for NurOwn underscores continued interest and potential therapeutic value for the investigational therapy.

Negatives

• The company's cash, cash equivalents, and restricted cash balance was critically low at approximately $0.23 million as of September 30, 2025.
• The promissory note involves a significant original issue discount of $18,750 on a $143,750 principal amount, and the conversion terms include a 25% discount to the lowest trading price, indicating highly dilutive potential for existing shareholders.
• The company continues to operate at a net loss of $2.1 million for Q3 2025.
• Shares outstanding increased substantially from 6,141,762 at December 31, 2024, to 11,034,775 at September 30, 2025, reflecting significant prior dilution.

Risks

• The company's ability to continue as a going concern is a significant risk, as explicitly mentioned in forward-looking statements, given the low cash balance and ongoing operational losses.
• Potential for substantial shareholder dilution from the conversion of the promissory note into common stock at a 25% discount to market price.
• Reliance on the success of the Phase 3b clinical trial for NurOwn and subsequent regulatory approval for future viability.
• The need for additional capital raises in the near future to fund ongoing operations and clinical trials, which could lead to further dilution or unfavorable financing terms.
• The promissory note includes various events of default that could trigger immediate repayment or conversion at unfavorable terms, including failure to make amortization payments, failure to issue conversion shares, or breach of covenants.

Future Outlook

The company is advancing pre-initiation activities for its Phase 3b ENDURANCE clinical trial of NurOwn for ALS, following FDA clearance. This trial is designed to generate confirmatory data to support a potential Biologics License Application (BLA). A conference call and webcast for the investment community are planned for late Q4 2025 or early Q1 2026 to provide further updates on the NurOwn Phase 3 program.

Management Comments

• "We are making steady progress toward stabilizing our financial situation and initiating our Phase 3b study of NurOwn, designed to generate confirmatory data to support a potential BLA submission."
• "We have been working closely with our network of clinical sites and with our selected manufacturing partners to ensure operational readiness."
• "We also continue to engage with regulatory authorities and are pleased that the FDA has cleared the planned clinical study."
• "We are committed to working with the ALS community and believe that, if approved, NurOwn will be a valuable therapeutic approach that would slow disease progression and improve quality of life for people afflicted with ALS."

Industry Context

Brainstorm Cell Therapeutics operates in the highly specialized and capital-intensive field of neurodegenerative disease therapeutics, specifically focusing on ALS with its autologous stem cell therapy, NurOwn. The FDA clearance for a Phase 3b trial is a significant milestone in this industry, indicating regulatory confidence in the trial design. The involvement of the ALS community through a Citizen Petition highlights the urgent unmet medical need and patient advocacy in this disease area. The company's financial challenges, including low cash reserves and reliance on dilutive financing, are common for biotech firms in advanced clinical development stages, where substantial funding is required to bring therapies to market.

Comparison to Industry Standards

• None mentioned in the filing.

Stakeholder Impact

• Shareholders face potential significant dilution from the conversion of the promissory note due to its discounted conversion price and the substantial increase in outstanding shares over the past year.
• Patients with ALS and the ALS community may benefit from the advancement of the NurOwn Phase 3b trial, offering hope for a new therapeutic option.
• Employees' job security is tied to the company's ability to secure sufficient funding to continue operations and advance its clinical programs.
• Creditors (Labrys Fund II, L.P.) have secured a convertible promissory note with specific repayment terms and default provisions, providing a mechanism for recovery or equity conversion.

Next Steps

• Initiate the Phase 3b ENDURANCE clinical trial for NurOwn, expected to enroll approximately 200 participants.
• Generate confirmatory data from Part A of the Phase 3b trial to support a potential Biologics License Application (BLA).
• Host a conference call and webcast for the investment community in late Q4 2025 or early Q1 2026 to provide further updates on the NurOwn Phase 3 program.
• Make scheduled amortization payments on the promissory note starting May 11, 2026.

Key Dates

Recommendation

The company shows progress in its clinical development with FDA clearance for a Phase 3b trial for NurOwn, which is a significant positive for a biotech firm. However, its financial health is extremely fragile, evidenced by a very low cash balance and ongoing net losses. The recent debt financing, while providing immediate capital, comes with highly dilutive conversion terms. For existing investors, holding the stock might be justified by the potential upside of NurOwn's clinical success, but it carries substantial risk due to the company's precarious financial position and the high likelihood of further dilution. New investors should approach with extreme caution, as the risk-reward profile is highly speculative without a clear path to sustained funding or market approval.

Keywords

Biotech, Neurodegenerative, ALS, NurOwn, Stem Cell Therapy, Clinical Trial, FDA Clearance, Debt Financing, Q3 Earnings, Financial Results